Same‐day discharge following catheter ablation and venous closure with VASCADE MVP: A postmarket registry

摘要

Abstract Introduction Early and safe ambulation can facilitate same‐day discharge (SDD) following catheter ablation, which can reduce resource utilization and healthcare costs and improve patient satisfaction. This study evaluated procedure success and safety of the VASCADE MVP venous vascular closure system in patients with atrial fibrillation (AF). Methods The AMBULATE SDD Registry is a two‐stage series of postmarket studies in patients with paroxysmal or persistent AF undergoing catheter ablation followed by femoral venous access‐site closure with VASCADE MVP. Efficacy endpoints included SDD success, defined as the proportion of patients discharged the same day who did not require next‐day hospital intervention for procedure/access site–related complications, and access site sustained success within 15 days of the procedure. Results Overall, 354 patients were included in the pooled study population, 151 (42.7) treated for paroxysmal AF and 203 (57.3) for persistent AF. SDD was achieved in 323 patients (91.2) and, of these, 320 (99.1) did not require subsequent hospital intervention based on all study performance outcomes. Nearly all patients (350 of 354; 98.9) achieved total study success, with no subsequent hospital intervention required. No major access‐site complications were recorded. Patients who had SDD were more likely to report procedure satisfaction than patients who stayed overnight. Conclusion In this study, 99.7 of patients achieving SDD required no additional hospital intervention for access site–related complications during follow‐up. SDD appears feasible and safe for eligible patients after catheter ablation for paroxysmal or persistent AF in which the VASCADE MVP is used for venous access‐site closure.